Veru Inc. (NASDAQ:VERU – Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders purchased 4,729 put options on the company. This represents an increase of 95% compared to the average volume of 2,430 put options.
Institutional Trading of Veru
Large investors have recently made changes to their positions in the company. Weaver Consulting Group grew its stake in shares of Veru by 27.4% in the 1st quarter. Weaver Consulting Group now owns 88,838 shares of the company’s stock valued at $44,000 after buying an additional 19,133 shares during the period. Wells Fargo & Company MN boosted its stake in Veru by 37.1% during the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company’s stock valued at $49,000 after purchasing an additional 20,430 shares during the last quarter. Integrated Wealth Concepts LLC boosted its stake in Veru by 31.3% during the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company’s stock valued at $56,000 after purchasing an additional 20,500 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its stake in Veru by 52.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock valued at $57,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Cetera Investment Advisers boosted its stake in Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company’s stock valued at $62,000 after purchasing an additional 19,724 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.
Veru Stock Down 3.3%
Shares of VERU stock opened at $0.58 on Wednesday. The firm has a 50 day moving average of $0.55 and a 200-day moving average of $0.61. The company has a market cap of $85.06 million, a price-to-earnings ratio of -2.42 and a beta of -0.80. Veru has a 52 week low of $0.45 and a 52 week high of $1.42.
Veru Company Profile
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
- Five stocks we like better than Veru
- Election Stocks: How Elections Affect the Stock Market
- Analyst Downgrades Joby, But Overlooks Major Regulatory Wins
- A Deeper Look at Bid-Ask Spreads
- U.S. Steel Stock Burns the Bears With Surprise Upside Move
- Golden Cross Stocks: Pattern, Examples and Charts
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.